This study highlights the vital role of caregivers in supporting women living with pulmonary arterial hypertension (PAH) and ...

A joint study between the Nursing School of North Henan Medical University (Xinxaing, China) and The First Affiliated Hospital of Harbin Medical University (Harbin, China) used gas chromatography–mass ...

A trial of Insmed’s TPIP suggests daily doses of the inhaled dry powder are well tolerated and may improve blood flow in ...

Treprostinil palmitil inhalation powder (TPIP) for pulmonary arterial hypertension (PAH) showed promising results in a ...

⊥ Third Institute of Oceanography, State Oceanic Administration, Xiamen 361005, P.R. China # SOA Key Laboratory for Polar Science, Polar Research Institute of China, Shanghai 200136, P.R. China ...

TPIP trial exceeds expectations; Phase 3 studies to begin by early 2026 Shares in Insmed Incorporated (NASDAQ:INSM) closed 28 ...

With what Insmed calls an "outstanding" phase 2 win for its treprostinil palmitil inhalation powder (TPIP) in patients with ...

The DNA lesions in the PAH gene which presumably cause PKU in Spain have now been identified. The goal of the present study was to enlarge the knowledge of the disease-causing mechanisms and ...

No patient had unidentified alleles in both chromosomes. This study describes the mutations of PAH gene in the Estonian population. Although the number of samples studied is not very large ...

Standard ESC/ERS risk tools used in PAH had lower accuracy in patients with obesity, a comorbidity frequently found in patients with PAH. In pulmonary arterial hypertension (PAH), 5-year mortality is ...

It serves as an epigenetic modulator, which means it regulates gene activity without altering the DNA sequence. According to Cereno, the upcoming Phase 2b trial will test CS1 against a placebo in a ...